SCHEMBL4767994

SCHEMBL4767994

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)NC[C@@H](O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.53
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 1/20 0.45
RECQL P46063 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
ITGAV P06756 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767999 1.00 GAA (0.53) GAAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4771203 0.93 GAA (0.60) GAAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5571323 0.84 GAA (0.50) GAAALDH1A1SMN1; SMN2NPC1KMT2A
SCHEMBL5567848 0.84 GAA (0.50) GAAALDH1A1SMN1; SMN2NPC1KMT2A
SCHEMBL4775207 0.84 GAA (0.69) GAAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4773061 0.82 GAA (0.59) GAAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4777302 0.82 GAA (0.56) GAAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4777649 0.81 GAA (0.55) GAAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4773306 0.80 GAA (0.52) GAAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4770931 0.80 GAA (0.62) GAAALDH1A1SMN1; SMN2KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885ALDH1A1 2159/4885SMN1; SMN2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.